MD Hyperbaric announces two major leadership additions to their executive team as they accelerate toward a next phase of growth, focused on providing more patients across the country with access to Hyperbaric Oxygen Therapy in a clinical setting design to improve health and wellness outcomes.
February 16, 2026
New York, NY — February 16, 2026 – MD Hyperbaric is proud to announce two major additions to its executive leadership team: Dr. Jason Sonners has joined as Chief Clinical Officer (CCO), and Dave Globig has joined as Chief Strategy Officer (CSO).
These appointments represent a significant milestone in MD Hyperbaric’s continued growth and commitment to becoming the nation’s most trusted and clinically credible hyperbaric oxygen therapy (HBOT) platform.
Strengthening Clinical Leadership: Dr. Jason Sonners, Chief Clinical Officer
Dr. Sonners brings more than two decades of experience as a hyperbaric clinic operator, along with national leadership in advancing the hyperbaric field through education and professional collaboration. Throughout his career, Dr. Sonners has held leadership roles with IBUM and IHA, and has played an active role in expanding awareness of hyperbaric medicine and its potential benefits across the country.
At MD Hyperbaric, Dr. Sonners will provide strategic clinical leadership across the organization, supporting medical directors, and strengthening protocol development to drive outcomes for patients accessing medical-grade HBOT.
MD Hyperbaric’s model is built around delivering medical-grade hyperbaric therapy in a professional, protocol-driven environment – bridging the gap between clinical medicine and accessible, outcomes-focused care. Dr. Sonners’ experience and leadership are a strong compliment for the next stage of the company’s growth.
Accelerating Strategy and Scale: Dave Globig, Chief Strategy Officer
MD Hyperbaric is also excited to welcome Dave Globig as Chief Strategy Officer.
Dave most recently served as the CEO of Aviv Clinics, where he spent the last six years leading what is widely recognized as the world’s largest and most published off-label HBOT clinic, based in Orlando, Florida. Over his career, Dave has developed deep expertise in healthcare strategy, operations, and growth, particularly in building scalable clinical models rooted in quality, outcomes, and patient trust.
Dave’s experience at the highest levels of the HBOT industry brings a unique strategic advantage to MD Hyperbaric as the company expands nationally and continues to build meaningful relationships across the broader healthcare ecosystem.
Looking Ahead
MD Hyperbaric is currently on a strong growth trajectory, with the company expanding across new markets and strengthening its operational foundation. With Dr. Sonners and Dave Globig joining the leadership team, MD Hyperbaric is accelerating toward its goal of reaching 25+ centers by the end of the year.
The company believes the future of hyperbaric therapy will be defined by clinical credibility, operational excellence, and measurable outcomes. These leadership additions reflect MD Hyperbaric’s commitment to building a national platform that raises the standard for hyperbaric care, both for patients and for the broader medical community.
MD Hyperbaric is thrilled to welcome Dr. Sonners and Dave Globig to the team and looks forward to the impact they will help drive as the company enters its next phase of scale.
About MD Hyperbaric
MD Hyperbaric is a premier provider of medical-grade hyperbaric oxygen therapy, committed to enhancing health and wellness through advanced therapeutic techniques. With a growing network of corporate and franchise-owned locations across the country, MD Hyperbaric is dedicated to delivering exceptional care and personalized solutions to support optimal recovery and overall well-being. For more information, and to learn about franchise opportunities, visit https://mdhyperbaric.com.